Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)
AstraZeneca pushes Tagrisso-chemo combo following positive progression-free survival data
AstraZeneca’s EGFR inhibitor Tagrisso (osimertinib) could be on its way to adding another lung cancer indication after the company said on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
